|
10 Jun 2022 |
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
|
|
08 Jun 2022 |
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population
|
|
07 Jun 2022 |
CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022
|
|
07 Jun 2022 |
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting
|
|
05 Jun 2022 |
OriCell Reports OriCAR-017 Phase I POLARIS study Data in Oral Presentation at ASCO 2022
|
|
05 Jun 2022 |
CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
|
|
03 Jun 2022 |
VectorY presents new pre-clinical data at the European Network for the Cure of ALS (ENCALS)
|
|
03 Jun 2022 |
Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers
|
|
03 Jun 2022 |
New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS
|
|
02 Jun 2022 |
Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
|
|
02 Jun 2022 |
Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
|
|
01 Jun 2022 |
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies
|
|
01 Jun 2022 |
Eureka Therapeutics and City of Hope Treat First Patient with GPC3 Targeting ARTEMIS® T Cells (ECT204) for Advanced Liver Cancer
|
|
01 Jun 2022 |
Amgen announces positive topline phase 2 data for investigational olpasiran in adults with elevated lipoprotein(a)
|
|
29 May 2022 |
IASO Biotherapeutics' Equecabtagene Autoleucel, the World's First CAR-T for Treatment of NMOSD, Receives IND Application Acceptance by NMPA
|
|
28 May 2022 |
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
|
|
27 May 2022 |
Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment
|
|
27 May 2022 |
Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)
|
|
27 May 2022 |
Data from Phase 2 PILOT Study of Bristol Myers Squibb’s CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy
|
|
27 May 2022 |
CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
|
|
25 May 2022 |
Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic
|
|
25 May 2022 |
FDA Accepts CSL Behring’s Biologics License Application for Etranacogene Dezaparvovec for Priority Review
|
|
23 May 2022 |
Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus
|
|
23 May 2022 |
Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
|
|
20 May 2022 |
Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE MultiStem Ischemic Stroke Study
|
